Edwards Lifesciences Corp (EW)vsMyomo Inc (MYO)
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
MYO
Myomo Inc
$1.30
0.00%
HEALTHCARE · Cap: $55.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 14953% more annual revenue ($6.51B vs $43.26M). EW leads profitability with a 15.4% profit margin vs -33.5%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
MYO
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Intrinsic value data unavailable for MYO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Revenue surging 21.3% year-over-year
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Trading at 8.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : MYO
The strongest argument for MYO centers on Revenue Growth. Revenue growth of 21.3% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Bear Case : MYO
The primary concerns for MYO are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.44 is elevated, increasing financial risk.
Key Dynamics to Monitor
EW profiles as a mature stock while MYO is a growth play — different risk/reward profiles.
MYO carries more volatility with a beta of 1.50 — expect wider price swings.
MYO is growing revenue faster at 21.3% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 29/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Myomo Inc
HEALTHCARE · MEDICAL DEVICES · USA
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?